FRANKLIN LAKES, N.J., May 13 BD (Becton,
Dickinson and Company) (NYSE: BDX) announced today that it has acquired all of
the outstanding stock of Cytopeia, a privately held Washington corporation
based in Seattle that develops and markets advanced flow cytometry cell
sorting instruments.
Financial terms of this transaction were not disclosed. The acquisition
is not expected to have a material impact on BD's fiscal year 2008 earnings.
"This strategic acquisition brings new technologies and capabilities that
will enhance BD's ability to address growing customer needs in advanced
applications, such as cell therapy research," said William A. Kozy, BD
Executive Vice President. "This transaction reflects our commitment to
bringing innovative tools to life scientists and will allow us to rapidly
enter emerging areas of cell-based research."
Cytopeia's Influx(TM) cell sorter offers BD an open, configurable cell
sorting platform that can be fully optimized for researchers' unique
application-specific requirements. This high level of choice and control is
particularly important for life science research on the leading edge of
biomedical discovery. The Influx cell sorter is suited for a range of
applications including cell therapy research, stem cell research, drug
discovery and development, as well as marine biology. It complements the BD
FACSAria(TM) II system -- the platform of choice in research labs around the
world for a broad range of immunology cell sorting and multi-color
applications.
Through the acquisition, BD gains the scientific leadership and insights
of Dr. Ger van den Engh, a renowned innovator in flow cytometry. Dr. van den
Engh will join BD Biosciences, a segment of BD, as Vice President, Advanced
Cytometry. In this role, he will manage continuing research and technology
development activities in Seattle.
"In addition to access to BD Biosciences' unparalleled portfolio of
cellular research tools, Cytopeia's customers will benefit from our high-
quality manufacturing and global customer support capabilities," Kozy said.
BD Biosciences is a pioneer and leader in the field of flow cytometry for
cellular analysis. BD manufactured the first BD FACS(TM) (fluorescence-
activated cell sorting) system in 1973. Today, BD Biosciences offers broad
portfolios of research and clinical flow cytometry platforms and reagents
designed for cellular characterization and sorting, as well as tools to aid in
drug discovery and the growth of living cells and tissue.
About BD
BD, a leading global medical technology company that manufactures and
sells medical devices, instrument systems and reagents, is dedicated to
improving people's health throughout the world. BD is focused on improving
drug therapy, enhancing the quality and speed of diagnosing infectious
diseases, and advancing research and discovery of new drugs and vaccines. The
Company's capabilities are instrumental in combating many of the world's most
pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New
Jersey, BD employs approximately 28,000 people in approximately 50 countries
throughout the world. The Company serves healthcare institutions, life science
researchers, clinical laboratories, industry and the general public. For more
information, please visit www.bd.com.
This press release contains certain estimates and other forward-looking
statements (as defined under Federal securities laws) regarding BD's
performance, including future revenues, products, earnings per share and
income, or events or developments that BD expects to occur or anticipates
occurring in the future. All such statements are based upon current
expectations of BD and involve a number of business risks and uncertainties.
Actual results could vary materially from anticipated results described,
implied or projected in any forward-looking statement. With respect to
forward-looking statements c
Category:
